XOMA-Logo-Final.png
XOMA Initiates Clinical Trial of NEUPREX At Harvard Medical School in Allogeneic Hematopoietic Stem Cell Transplantation
January 09, 2007 09:00 ET | XOMA Corporation
BERKELEY, Calif., Jan. 9, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) announced today that it has initiated an open label, dose escalating Phase I/II clinical trial of NEUPREX(r) (opebacan) in...
XOMA-Logo-Final.png
XOMA Announces Pre-Clinical and Clinical Progress On HCD122
December 11, 2006 10:40 ET | XOMA Corporation
ORLANDO, Fla., Dec. 11, 2006 (PRIME NEWSWIRE) -- At the annual meeting of the American Society of Hematology (ASH), XOMA Ltd. (Nasdaq:XOMA), along with Novartis, announced pre-clinical and preliminary...
XOMA-Logo-Final.png
XOMA to Present At Piper Jaffray's 18th Annual Health Care Conference On December 1, 2006
November 29, 2006 14:21 ET | XOMA Corporation
BERKELEY, Calif., Nov. 29, 2006 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) announced today that Paul Goodson, XOMA's Sr. Director, Investor Relations and Robert H. Gundel, XOMA's Vice President of...
XOMA-Logo-Final.png
XOMA Reports Third Quarter 2006 Results
November 09, 2006 16:04 ET | XOMA Corporation
BERKELEY, Calif., Nov. 9, 2006 (PRIMEZONE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics for cancer and immunological disorders, today announced its...
XOMA-Logo-Final.png
XOMA Receives European Certification to Manufacture Investigational Medicinal Products
November 06, 2006 03:10 ET | XOMA Corporation
BERKELEY, Calif., Nov. 6, 2006 (PRIMEZONE) -- XOMA Ltd. (Nasdaq:XOMA) today announced that its cGMP pharmaceutical manufacturing facilities have received Investigational Medicinal Products...
XOMA-Logo-Final.png
XOMA and Takeda Establish Collaboration for Therapeutic Antibody Discovery and Development
November 02, 2006 03:05 ET | XOMA Corporation
BERKELEY, Calif. and OSAKA, Japan, Nov. 2, 2006 (PRIMEZONE) -- XOMA Ltd. (Nasdaq:XOMA) and Takeda Pharmaceutical Company Limited (TSE4502:Takeda) today announced that they have entered into an...
XOMA-Logo-Final.png
XOMA Announces November 9 Conference Call and Webcast Discussion of Third Quarter 2006 Results
November 01, 2006 14:00 ET | XOMA Corporation
BERKELEY, Calif., Nov. 1, 2006 (PRIMEZONE) -- XOMA Ltd. (Nasdaq:XOMA) will issue a news release announcing its third-quarter financial results for the quarter ended September 30, 2006, on Thursday,...
XOMA-Logo-Final.png
XOMA to Humanize Attenuon's Novel Anti-Cancer Antibody
October 03, 2006 09:00 ET | XOMA Corporation
BERKELEY, Calif. and SAN DIEGO, Oct. 3, 2006 (PRIMEZONE) -- XOMA Ltd. (Nasdaq:XOMA) and Attenuon, LLC today announced an agreement for XOMA to utilize its Human Engineering(tm) (HE(tm)) technology to...
XOMA-Logo-Final.png
XOMA and Affimed Sign Antibody Cross-License and Collaboration Agreement
October 02, 2006 09:00 ET | XOMA Corporation
BERKELEY, Calif. and HEIDELBERG, Germany, Oct. 2, 2006 (PRIMEZONE) -- XOMA Ltd. (Nasdaq:XOMA) and Affimed Therapeutics AG announced today that they have signed a cross-license and collaboration...
XOMA-Logo-Final.png
XOMA Announces Conference Presentation Schedule
September 29, 2006 18:04 ET | XOMA Corporation
BERKELEY, Calif., Sept. 29, 2006 (PRIMEZONE) -- XOMA Ltd. (Nasdaq:XOMA) today announced its plans for its chief financial officer, Mr. David Boyle, to present an overview of its business strategy and...